Core Insights - EUDA Health Holdings Limited has secured distribution rights for T-cell immunotherapies in Malaysia from Shenzhen Inno Immune Co. Ltd, marking a significant expansion into advanced cell therapy [1][2] - The T-cell immunotherapy package will be priced at USD 8,000 per treatment, significantly lower than traditional costs in the region, making it more accessible [4] - This partnership is part of EUDA's strategy to diversify its healthcare portfolio and focus on regenerative and longevity medicine, addressing the healthcare needs of an aging population in Asia [5][6] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to transform healthcare from reactive treatment to proactive, longevity-focused care [6] - The company aims to address the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [6] - EUDA also operates a property management business in Singapore, further diversifying its operations [6] Strategic Partnerships - The agreement with Shenzhen Inno is facilitated by Guangdong Key Lock Health Management Co., Ltd, which has a long-term strategic partnership with both EUDA and Shenzhen Inno [3] - This partnership is expected to enhance EUDA's offerings in immune-enhancing therapies, leveraging Shenzhen Inno's scientific and institutional backing [5][8]

Core Viewpoint - Minovia Therapeutics is advancing its mitochondrial augmentation technology (MAT) to address mitochondrial diseases and age-related decline, with its lead program MNV-201 receiving FDA Fast Track and Rare Pediatric Disease designations, and is preparing for its first pivotal clinical trial [1][3][6] Company Overview - Minovia Therapeutics is a clinical-stage biotechnology company based in Haifa, Israel, focused on developing therapies to treat mitochondrial diseases and combat aging [1][4][14] - The company is entering a business combination with Launch One Acquisition Corp, which will create a publicly traded entity named Mito US One Ltd, expected to be listed on Nasdaq [1][6][11] Technology and Product Development - Minovia's MAT platform aims to restore energy production in cells by enriching them with healthy mitochondria, potentially addressing a wide range of diseases including neurodegenerative and metabolic disorders [4][5] - The lead product, MNV-201, is currently in a Phase 2 trial for Pearson Syndrome and a Phase 1b study for low-risk Myelodysplastic Syndrome (MDS) [6][14] - The company has treated 23 patients with various mitochondrial conditions, showing significant improvements in health outcomes without adverse effects [5][6] Financial Aspects and Transaction Details - The business combination values Minovia at a pre-money equity valuation of $180 million, with additional financing expected to support its growth and development pipeline [10] - Launch One's trust account currently holds approximately $239.7 million in cash, which may be partially available to the combined company after the transaction [6][10] Market Potential - Minovia aims to become a leader in the $1+ trillion longevity and regenerative medicine market, with plans to launch MAT-based offerings through global partnerships starting in 2026 [8][9] - The company believes its accumulated clinical data and preclinical results position it well to capitalize on the growing demand for mitochondrial regenerative medicine [8][9]